Intrigued by our compelling results in the combination therapy involving CD244-deficient macrophages and anti-PD-L1 antibody, which demonstrated a significant reduction in tumor size compared to the control groups, we assert that the impact of CD244 removal in macrophages profoundly transforms the tumor immune microenvironment, holding clinical significance. The gene discussed is CD244; the disease is neoplasm.